The efficacy of pyrimethamine-sulfadoxine (Fansidar®) in the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children

Transactions of the Royal Society of Tropical Medicine and Hygiene

Volumn 94, Issue 1, 2000, Pages 83-84

  Ogutu, B R ^a,b,c,d   Smoak, B L ^b,c   Nduati, R W ^a   Mbori Ngacha, D A ^a   Mwathe, F ^b   Shanks, G D ^b,c  

^a UNIVERSITY OF NAIROBI   (Kenya)

^b KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

^c US Army Medical Research Unit Kenya   (United States)

^d NONE   (Kenya)

Author keywords

Chemotherapy; Children; Kenya; Malaria; Plasmodium falciparum; Pyrimethamine sulfadoxine

Indexed keywords

ANTIMALARIAL AGENT; FANSIDAR; PYRIMETHAMINE; SULFADOXINE;

ARTICLE; CHILD; DRUG EFFICACY; FEMALE; HUMAN; INFANT; KENYA; MAJOR CLINICAL STUDY; MALARIA; MALE; PLASMODIUM FALCIPARUM; TREATMENT OUTCOME;

EID: 0034001501     PISSN: 00359203     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0035-9203(00)90450-4     Document Type: Article

References (10)

1. Anabwani, G. M., Esamai, F. O. & Menya, D. A. (1996). A randomised controlled trial to assess the relative efficacy of chloroquine, amodiaquine, halofantrine, and Fansidar® in the treatment of uncomplicated malaria in children. East African Medical Journal, 73, 155-158.
2. Clarke, D., Odialla, H., Ouma, J., Kenny, V., MacCabe, R., Rapuoda, B. & Watkins, W. M. (1996). A malariometric survey in Turkana District, Kenya: chemosensitivity in vivo of Plasmodium falciparum infections and identity of the vector. Transactions of the Royal Society of Tropical Medicine and Hygiene, 90, 302-304.
3. Hagos, B., Khan, B., Ofulla, A. V. O., Kariuki, D. & Martin, S. K. (1993). Response of falciparum malaria to chloroquine and three second line antimalarial drugs in Kenyan coastal school age population. East African Medical Journal, 70, 620-623.
4. Keuter, M., van Eijk, A., Hoogstrate, M., Raasveld, M., van de Ree, M., Ngwawe, W. A., Watkins, W. M., Were, J. B. O. & Brandling-Bennett A. D. (1990). Comparison of chloroquine, pyrimethamine and sulfadoxine, and chlorproguanil and dapsone as treatment for falciparum malaria in pregnant and non-pregnant women, Kakamega district, Kenya. British Medical Journal, 301, 466-470.
5. Nguyen-Dinh, P., Spencer, H. C., Chemangey-Masaba, S. & Churchill, F. C. (1982). Susceptibility of Plasmodium falciparum to pyrimethamine and sulfadoxine/pyrimethamine in Kisumu, Kenya. Lancet, i, 823-825.
6. Rapuoda, B. A. & Achola, P. (1984). Studies on malaria and its vectors in Nairobi: a review of the distribution of vectors and the prevalence of the disease. KEMRI/KETRI Annual Medical Conference, Nairobi, Kenya.
7. Spencer, H. C., Watkins, W. M., Sixsmith, D. G. & Koech, D. K. (1986). Response of Plasmodium falciparum to dihydrofolate reductase inhibitors in Malindi, Kenya. Transactions of the Royal Society of Tropical Medicine and Hygiene, 80, 201-203.
8. Watkins, W. M. (1995). Pharmacology and pharmokinetics of new antimalarials. Médecine Tropicale, 55, 33-36.
9. WHO (1973). Chemotherapy of Malaria and Resistance to Antimalarials. Geneva: World Health Organization, Technical Report Series, no. 529.
10. WHO (1996). Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Geneva: World Health Organization. WHO/ MAL/96.1077.